

Ricardo Pasquini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6832112/publications.pdf>

Version: 2024-02-01

51
papers

709
citations

759233

12
h-index

580821

25
g-index

52
all docs

52
docs citations

52
times ranked

996
citing authors

#	ARTICLE	IF	CITATIONS
1	Kidney complications in 107 Fanconi anemia patients submitted to hematopoietic cell transplantation. <i>European Journal of Pediatrics</i> , 2022, 181, 715-723.	2.7	4
2	Itinerário terapêutico de pacientes hematólogicos: a importância do diagnóstico precoce. <i>Research, Society and Development</i> , 2022, 11, e50611427670.	0.1	0
3	Transplantation for Fanconi anaemia: lessons learned from Brazil. <i>Lancet Haematology</i> , 2022, 9, e228-e236.	4.6	15
4	Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. <i>Leukemia</i> , 2021, 35, 440-453.	7.2	159
5	The impact of donor-specific anti-human leukocyte antigen antibodies in salvage haploidentical hematopoietic cell transplantation with posttransplant cyclophosphamide in patients with nonmalignant disorders. <i>Hla</i> , 2021, 97, 493-504.	0.6	4
6	Analysis of baseline characteristics, disease burden and long-term follow-up of 167 patients with Paroxysmal Nocturnal Hemoglobinuria at a single center in Brazil. <i>Blood Cells, Molecules, and Diseases</i> , 2021, 92, 102605.	1.4	4
7	Ocular Manifestations in Patients With Fanconi Anemia: A Single Center Experience Including 106 Patients. <i>Journal of Pediatrics</i> , 2021, , .	1.8	4
8	Investigation of MHC gamma block C4A and C4B polymorphisms in unrelated hematopoietic stem cell transplantation. <i>Hematology, Transfusion and Cell Therapy</i> , 2020, 42, 221-229.	0.2	2
9	Impact of CD34 Cell Dose and Conditioning Regimen on Outcomes after Haploidentical Donor Hematopoietic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide for Relapsed/Refractory Severe Aplastic Anemia. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2311-2317.	2.0	26
10	Outcomes after Haploidentical Stem Cell Transplantation with Post-Transplantation Cyclophosphamide in Patients with Primary Immunodeficiency Diseases. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1923-1929.	2.0	34
11	The challenge of long-term follow-up of survivors of childhood acute leukemia after hematopoietic stem cell transplantation in resource-limited countries: A single-center report from Brazil. <i>Pediatric Transplantation</i> , 2020, 24, e13691.	1.0	2
12	Transplantation of Hematopoietic Stem Cells for Primary Immunodeficiencies in Brazil: Challenges in Treating Rare Diseases in Developing Countries. <i>Journal of Clinical Immunology</i> , 2018, 38, 917-926.	3.8	13
13	Mutations in the breakpoint cluster region-Abelson murine leukemia 1 gene in Brazilian patients with chronic myeloid leukemia. <i>Hematology, Transfusion and Cell Therapy</i> , 2018, 40, 363-367.	0.2	1
14	Late chimerical status after bone marrow transplantation in severe aplastic anemia according to two different preparatory regimens. <i>Hematology, Transfusion and Cell Therapy</i> , 2018, 40, 112-119.	0.2	2
15	Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide for Children and Adolescents with Fanconi Anemia. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 310-317.	2.0	50
16	Long-term Survival, Organ Function, and Malignancy after Hematopoietic Stem Cell Transplantation for Fanconi Anemia. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1257-1263.	2.0	56
17	Patients' perceptions about diagnosis and treatment of chronic myeloid leukemia: a cross-sectional study among Brazilian patients. <i>Sao Paulo Medical Journal</i> , 2015, 133, 471-479.	0.9	4
18	Telomere Biology Gene Mutation and Transplant Outcome in Patients with Dyskeratosis Congenita. <i>Blood</i> , 2015, 126, 4785-4785.	1.4	0

#	ARTICLE	IF	CITATIONS
19	Bone mineral density, vitamin D, and nutritional status of children submitted to hematopoietic stem cell transplantation. <i>Nutrition</i> , 2014, 30, 654-659.	2.4	27
20	Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib. <i>Blood</i> , 2014, 124, 729-736.	1.4	84
21	ENESTnd 5-year (y) update: Long-term outcomes of patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with frontline nilotinib (NIL) versus imatinib (IM).. <i>Journal of Clinical Oncology</i> , 2014, 32, 7073-7073.	1.6	21
22	Autologous Transplantation of Bone Marrow Adult Stem Cells for the Treatment of Idiopathic Dilated Cardiomyopathy. <i>Arquivos Brasileiros De Cardiologia</i> , 2014, 103, 521-9.	0.8	1
23	Feasibility of Implementing Minimal Residual Disease Monitoring in Acute Promyelocytic Leukemia Patients Treated in Developing Countries. <i>Blood</i> , 2014, 124, 5354-5354.	1.4	0
24	Evaluation Of Seasonality In The Incidence Of Promyelocytic Leukemia In Brazil. <i>Blood</i> , 2013, 122, 5005-5005.	1.4	2
25	HLA and Aplastic Anemia: associations In Large Brazilian Cohorts. <i>Blood</i> , 2013, 122, 1237-1237.	1.4	0
26	Immune Reconstitution In Fanconi Anemia Patients Following Allogeneic Bone Marrow Transplantation. <i>Blood</i> , 2013, 122, 5487-5487.	1.4	0
27	Survey of the Frontline Treatment and Management of Chronic Myeloid Leukemia (CML) in a Real-World Setting: The 3rd Annual Update of the Worldwide Observational Registry Collecting Longitudinal Data on Management of Chronic Myeloid Leukemia Patients (The WORLD CML Registry). <i>Blood</i> , 2011, 118, 1695-1695.	1.4	1
28	Nilotinib Versus Imatinib in Patients (pts) with Newly Diagnosed Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENESTnd 36-Month (mo) Follow-up. <i>Blood</i> , 2011, 118, 452-452.	1.4	11
29	Complete Molecular Response (CMR) Rate with Nilotinib in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) without CMR After 2 Years on Imatinib: Preliminary Results From the Randomized ENESTcmr Trial of Nilotinib 400 Mg Twice Daily (BID) Vs Imatinib. <i>Blood</i> , 2011, 118, 606-606.	1.4	3
30	Comparison Between RT-PCR and RQ-PCR for Minimal Residual Disease Detection in Acute Promyelocytic Leukemia: The International Consortium on Acute Promyelocytic Leukemia (IC-APL) Experience,. <i>Blood</i> , 2011, 118, 3552-3552.	1.4	0
31	Bcr-Abl Mutations in Chronic Myeloid Leukemia - Impact on Survival and Treatment with Second Generation Inhibitorsâ€“ A Study on Behalf of Latin American Leukemia Net (Lalnet). <i>Blood</i> , 2011, 118, 1701-1701.	1.4	1
32	A Worldwide Observational Registry Collecting Longitudinal Data on Management of Chronic Myeloid Leukemia Patients (The WORLD CML Registry) â€“ 2nd Annual Interim Analysis. <i>Blood</i> , 2010, 116, 2292-2292.	1.4	2
33	Clonal Evolution In Fanconi Anemia; The Role of HOXA9. <i>Blood</i> , 2010, 116, 126-126.	1.4	0
34	Pregnancy after Allogeneic Hematopoietic Stem Cell Transplantation in Fanconi Anemia Patients: Multi-Institution Cases Report of Female Fertility Recovery. <i>Blood</i> , 2008, 112, 456-456.	1.4	0
35	HLA-Matched Related Donor Hematopoietic Cell Transplantation in 43 Patients with Fanconi Anemia Conditioned with 60 mg/kg of Cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 1455-1460.	2.0	69
36	Dasatinib or High-Dose Imatinib for Patients with Chronic-Phase Chronic Myeloid Leukemia Resistant to Standard-Dose Imatinib: 2-Year Follow-Up Data from START-R (CA180-017).. <i>Blood</i> , 2007, 110, 736-736.	1.4	7

#	ARTICLE	IF	CITATIONS
37	Imatinib Mesilate Versus Allogeneic Bone Marrow Transplantation for Patients with Chronic Myeloid Leukemia in First Chronic Phase - A Brazilian Point of View.. Blood, 2007, 110, 1096-1096.	1.4	0
38	Genetic Polymorphisms of Gluthatione-S-Transferases in Two Different Populations of Fanconi Anaemia Patients.. Blood, 2007, 110, 1981-1981.	1.4	0
39	Risk Factors for Graft Failure and Mortality after HLA-Matched Sibling Donor Transplant for Severe Aplastic Anemia in Brazil.. Blood, 2007, 110, 622-622.	1.4	1
40	Long Term Results of Allogeneic Stem Cell Transplant for CML in Pediatric Patients: A Study of 50 Cases Transplanted over 20 Years in a Single Institution.. Blood, 2006, 108, 5361-5361.	1.4	1
41	Comparative Functional Genomic Analysis of Myelodysplasia (MDS) in Fanconi Anemia (FA).. Blood, 2006, 108, 2636-2636.	1.4	0
42	Treatment of 287 Patients(pts) with Severe Aplastic Anemia(SAA) Using Cyclosporine-A(Csa) and Prednisone(Pred): 15 Year Follow-Up from a Single Institution.. Blood, 2004, 104, 2816-2816.	1.4	0
43	Unrelated Donor Stem Cell Transplantation for 36 Patients(pts) with Fanconi Anemia(FA): A Single Center Experience.. Blood, 2004, 104, 5171-5171.	1.4	0
44	Observacional Study for Evaluation of Quality of Life in Patients with Chronic Myeloid Leukemia (CML) in Use of Gleevec® (Imatinib Mesilate).. Blood, 2004, 104, 2932-2932.	1.4	0
45	Clonal Evolution of Fanconi Anemia (FA) Stem Cells Results from Clonal Adaptation and Clonal Selection. A Report from the International Fanconi Anemia Transcriptome Consortium.. Blood, 2004, 104, 3416-3416.	1.4	0
46	Five Years Update Results of Basiliximab (BAMAB) Therapy for Acute Refractory Graft Versus Host Disease (AGVHD).. Blood, 2004, 104, 5083-5083.	1.4	0
47	Cavernous sinus thrombosis caused by zygomycosis after unrelated bone marrow transplantation. Transplant Infectious Disease, 2001, 3, 231-234.	1.7	14
48	Central Nervous System Infections Following Bone Marrow Transplantation: An Autopsy Report of 27 Cases. Journal of Hematotherapy and Stem Cell Research, 2000, 9, 535-540.	1.8	54
49	Methemoglobinemia Secondary to Clofazimine Treatment for Chronic Graft-Versus-Host Disease. Blood, 1998, 92, 4872-4873.	1.4	17
50	Methemoglobinemia Secondary to Clofazimine Treatment for Chronic Graft-Versus-Host Disease. Blood, 1998, 92, 4872-4873.	1.4	1
51	Conhecimento de enfermeiros de hospital universitário sobre bactérias multirresistentes. Revista Da Rede De Enfermagem Do Nordeste, 0, 20, e41281.	0.2	2